PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
VXRT vs. BCRX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between VXRT and BCRX is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.3

Performance

VXRT vs. BCRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vaxart, Inc. (VXRT) and BioCryst Pharmaceuticals, Inc. (BCRX). The values are adjusted to include any dividend payments, if applicable.

-100.00%-50.00%0.00%50.00%100.00%NovemberDecember2025FebruaryMarchApril
-96.09%
51.64%
VXRT
BCRX

Key characteristics

Sharpe Ratio

VXRT:

-0.62

BCRX:

1.05

Sortino Ratio

VXRT:

-0.73

BCRX:

1.84

Omega Ratio

VXRT:

0.92

BCRX:

1.22

Calmar Ratio

VXRT:

-0.62

BCRX:

0.69

Martin Ratio

VXRT:

-1.80

BCRX:

5.25

Ulcer Index

VXRT:

34.15%

BCRX:

11.54%

Daily Std Dev

VXRT:

99.04%

BCRX:

57.55%

Max Drawdown

VXRT:

-98.69%

BCRX:

-97.74%

Current Drawdown

VXRT:

-98.53%

BCRX:

-77.66%

Fundamentals

Market Cap

VXRT:

$78.48M

BCRX:

$1.55B

EPS

VXRT:

-$0.33

BCRX:

-$0.43

PS Ratio

VXRT:

2.73

BCRX:

3.43

PB Ratio

VXRT:

1.33

BCRX:

56.59

Total Revenue (TTM)

VXRT:

$26.52M

BCRX:

$357.95M

Gross Profit (TTM)

VXRT:

$9.04M

BCRX:

$346.54M

EBITDA (TTM)

VXRT:

-$35.02M

BCRX:

$19.54M

Returns By Period

In the year-to-date period, VXRT achieves a -48.06% return, which is significantly lower than BCRX's -1.60% return.


VXRT

YTD

-48.06%

1M

-39.42%

6M

-58.05%

1Y

-54.49%

5Y*

-32.11%

10Y*

N/A

BCRX

YTD

-1.60%

1M

-3.77%

6M

-2.89%

1Y

67.04%

5Y*

16.41%

10Y*

-3.56%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

VXRT vs. BCRX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VXRT
The Risk-Adjusted Performance Rank of VXRT is 1616
Overall Rank
The Sharpe Ratio Rank of VXRT is 2020
Sharpe Ratio Rank
The Sortino Ratio Rank of VXRT is 2020
Sortino Ratio Rank
The Omega Ratio Rank of VXRT is 2323
Omega Ratio Rank
The Calmar Ratio Rank of VXRT is 1414
Calmar Ratio Rank
The Martin Ratio Rank of VXRT is 44
Martin Ratio Rank

BCRX
The Risk-Adjusted Performance Rank of BCRX is 8484
Overall Rank
The Sharpe Ratio Rank of BCRX is 8686
Sharpe Ratio Rank
The Sortino Ratio Rank of BCRX is 8585
Sortino Ratio Rank
The Omega Ratio Rank of BCRX is 8080
Omega Ratio Rank
The Calmar Ratio Rank of BCRX is 8080
Calmar Ratio Rank
The Martin Ratio Rank of BCRX is 8888
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

VXRT vs. BCRX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Vaxart, Inc. (VXRT) and BioCryst Pharmaceuticals, Inc. (BCRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for VXRT, currently valued at -0.62, compared to the broader market-2.00-1.000.001.002.003.00
VXRT: -0.62
BCRX: 1.05
The chart of Sortino ratio for VXRT, currently valued at -0.73, compared to the broader market-6.00-4.00-2.000.002.004.00
VXRT: -0.73
BCRX: 1.84
The chart of Omega ratio for VXRT, currently valued at 0.92, compared to the broader market0.501.001.502.00
VXRT: 0.92
BCRX: 1.22
The chart of Calmar ratio for VXRT, currently valued at -0.62, compared to the broader market0.001.002.003.004.00
VXRT: -0.62
BCRX: 0.77
The chart of Martin ratio for VXRT, currently valued at -1.80, compared to the broader market-5.000.005.0010.0015.0020.00
VXRT: -1.80
BCRX: 5.25

The current VXRT Sharpe Ratio is -0.62, which is lower than the BCRX Sharpe Ratio of 1.05. The chart below compares the historical Sharpe Ratios of VXRT and BCRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.00NovemberDecember2025FebruaryMarchApril
-0.62
1.05
VXRT
BCRX

Dividends

VXRT vs. BCRX - Dividend Comparison

Neither VXRT nor BCRX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

VXRT vs. BCRX - Drawdown Comparison

The maximum VXRT drawdown since its inception was -98.69%, roughly equal to the maximum BCRX drawdown of -97.74%. Use the drawdown chart below to compare losses from any high point for VXRT and BCRX. For additional features, visit the drawdowns tool.


-100.00%-90.00%-80.00%-70.00%-60.00%-50.00%NovemberDecember2025FebruaryMarchApril
-98.53%
-62.55%
VXRT
BCRX

Volatility

VXRT vs. BCRX - Volatility Comparison

Vaxart, Inc. (VXRT) has a higher volatility of 27.62% compared to BioCryst Pharmaceuticals, Inc. (BCRX) at 17.07%. This indicates that VXRT's price experiences larger fluctuations and is considered to be riskier than BCRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%NovemberDecember2025FebruaryMarchApril
27.62%
17.07%
VXRT
BCRX

Financials

VXRT vs. BCRX - Financials Comparison

This section allows you to compare key financial metrics between Vaxart, Inc. and BioCryst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab